A carregar...
Entry inhibitors: New advances in HCV treatment
Hepatitis C virus (HCV) infection affects approximately 3% of the world's population and causes chronic liver diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. Although current antiviral therapy comprising direct-acting antivirals (DAAs) can achieve a quite satisfying...
Na minha lista:
| Publicado no: | Emerg Microbes Infect |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4735057/ https://ncbi.nlm.nih.gov/pubmed/26733381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/emi.2016.3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|